Teva Entered Into An Agreement With JKI Co. Established By The Fund Managed And Operated By Private Equity Firm J-Will Partners Co., Through Which JKI Will Acquire Teva-Takeda; The Agreement Is Aligned With Teva's Pivot To Growth Strategy To Focus Its...
Teva Entered Into An Agreement With JKI Co. Established By The Fund Managed And Operated By Private Equity Firm J-Will Partners Co., Through Which JKI Will Acquire Teva-Takeda; The Agreement Is Aligned With Teva's Pivot To Growth Strategy To Focus Its...
Teva Entered Into An Agreement With JKI Co. Established By The Fund Managed And Operated By Private Equity Firm J-Will Partners Co., Through Which JKI Will Acquire Teva-Takeda; The Agreement Is Aligned With Teva's Pivot To Growth Strategy To Focus Its Business; No Financial Terms Disclosed
梯瓦與由股權投資公司J-Will Partners管理和運營的基金設立的JKI公司達成協議，通過該協議，JKI將收購梯瓦-武田；該協議符合梯瓦轉向增長策略以聚焦其業務；未透露任何財務條款。
- Teva entered into an agreement with JKI Co., Ltd. ("JKI") established by the fund managed and operated by private equity firm J-Will Partners Co., Ltd. ("J-Will"), through which JKI will acquire Teva-Takeda
- The agreement is aligned with Teva's Pivot to Growth strategy to focus its business
- The expected divestment of Teva-Takeda, Teva's business venture in Japan, which includes generics products and legacy products, will allow Teva to focus on bringing its innovative medicines to the Japanese market
- 梯瓦與由股權投資公司J-Will Partners管理和運營的基金設立的JKI公司達成協議，通過該協議，JKI將收購梯瓦-武田。
- 協議與梯瓦的增長策略相一致，以專注其業務。
- 預計剝離梯瓦在日本的業務創業公司梯瓦-武田，其中包括仿製藥和傳統產品，將使梯瓦能夠專注於將其創新藥品帶入日本市場。
TEL AVIV, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Today, Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced that it has entered into an agreement with JKI, established by the fund managed and operated by J-Will, whereby all shares of Teva Takeda Pharma Limited and its wholly owned subsidiary Teva Takeda Yakuhin Ltd. will be transferred to JKI.
2024年12月05日，以色列特拉維夫，今日，梯瓦製藥工業有限公司（紐交所和特拉維夫證券交易所：TEVA）宣佈，已與由J-Will管理和運營的基金設立的JKI達成協議，根據該協議，梯瓦武田製藥有限公司及其全資子公司梯瓦武田藥品有限公司的所有股份將被轉讓給JKI。
Teva recently communicated that it was open to exploring new strategic approaches in Japan, including a possible divestment of its Teva-Takeda business venture, in alignment with its Pivot to Growth strategy. The divestment will allow Teva to focus on its innovative medicines business in Japan.
梯瓦最近表示，願意探索在日本的新戰略方法，包括可能剝離其梯瓦-武田業務創業公司，以與其增長策略保持一致。剝離將使梯瓦能夠在日本專注於其創新藥品業務。
Teva expects the divestiture to be completed by 1 April, 2025, subject to standard closing conditions, including obtaining required regulatory approvals. All the employees of the business venture in Japan will remain employed, subject to the terms of the agreement.
梯瓦預計剝離將於2025年4月1日完成，視情況需滿足標準的閉幕條件，包括獲得必要的監管批准。日本業務創業公司的所有員工將繼續受僱，受協議條款約束。
